Oh, No. Alcohol-Based Sanitizers Losing Effectiveness Against Superbugs.
Hospital hand sanitizers not potent enough for superbug (Science)
Bacterial superbugs are becoming increasingly tolerant of alcohol, the key ingredient of the hand sanitizers used...
Our Favorite Incubator, Incubates! Telehealth in its Future?
True Nature|Mitesco has found an excellent first Company to incubate and help grow, called MyCare.The founders of the Minute Clinic are teaming up again...
Adding Immuron (IMRN) $2.57 to Superbug Watchlist.
CLICK FOR LIVE QUOTE
SUPER BUG STOCK REVIEW
Prevent Montezuma's Revenge BEFORE it starts! Immuron's direct to consumer product Travelan® is a huge hit with international...
VirnetX (VHC) Scores $440 Million and Citius Pharma (CTXR) Sees Market Expand to Over...
Internet Stock Review
Blast from the past scores big!
We added VirnetX (VHC) to the Watch List (Patent Stock Review, since shuttered) back in 2010....
Avenue Therapeutics (ATXI) Announces New Drug Application for IV Tramadol Accepted for Review by...
IV tramadol for the management of moderate to moderately severe pain in adults in a medically supervised health care setting.
$2.00 to $10 in...
Fortress Bio (FBIO) Inches Closer to $3.00 on Major News.
Fortress Bio (FBIO) Inches Closer to $3.00 on Major News.
Citius Pharma (CTXR) Inches Closer to the Next Phase III Data Announcement.
Citius Pharma Presenting at...
Citius (CTXR) Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal Trial
PHASE III PROGRESS
October 7th, 2019, Citius Completes 40% - Triggers Data Being Analyzed (is it working?).December 19th, 2019 - Data Analysis Back, Results Positive.February...
Okay, so What’s Next for Citius Pharma (CTXR) $1.16?
Dawson James Broker/Dealer Updates. Price Target Remains at $7.00.
"OK, So what’s Next? Topline data from the superior efficacy interim analysis should represent the next...
Citius Pharma (CTXR) $1.20. Price Target Upped to $4.00 at HC Wainright.
STREET INSIDER
H.C. Wainwright analyst Vernon Bernardino raised the price target on Citius Pharmaceuticals (NASDAQ: CTXR) to $4.00 (from $1.65) while maintaining a Buy rating.
The analyst commented,...
VIDEO: Dyadic (DYAI) CEO Explains What his Industry is Doing to Defeat Coronavirus (FoxNews).
Jan. 27, 2020 - 5:24 - Dyadic International CEO Mark Emalfarb discusses what’s being done to stop the spread of coronavirus and to...
Latest article
Jeffrey Gundlach: Reckoning is Coming.
Jeffrey Edward Gundlach is a businessman, fund manager, and philanthropist. He is the founder of DoubleLine Capital, an investment firm.
On 11 November 2020, Gundlach remarked in an interview with...
Who’s the Next Eric Sprott?
Eric Sprott, on Who is the Next Eric Sprott!
To say Eric Sprott has left a legendary mark on the world of mining investment would...
Perpetua (PPTA) Raises $300 Million.
Not a bad day in Idaho. $300 million banked! We look at the dip as a buying opportunity, as does John Paulson & Co.,...
